FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 61 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Does Sugar Feed Cancer? March 19, 2021 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Welcome to our new committee chairs November 22, 2022 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Load more HOT NEWS Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout Diving into our role in 50 top cancer drugs
